Solapamiento de asma grave y déficit de alfa-1-antitripsina: a propósito de un caso.
Resumen
Referencias
Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange
P, Mahadeva R, et al. European Respiratory Society
statement: diagnosis and treatment of pulmonary disease
in α1-antitrypsin deficiency. Eur Respir J. 2017;30:50.
GEMA 4.3. Guía Española para el Manejo del Asma. 2018.
www.gemasma.com.
Siri D, Farah H, Hogarth DK. Distinguishing alpha1-
antitrypsin deficiency from asthma. Ann Allergy Asthma
Immunol. 2013;111:458–64.
Eden E, Hammel J, Rouhani FN, Brantly ML, Barker AF,
Buist AS, et al. Asthma features in severe alpha1-antitrypsin
deficiency: experience of the National Heart, Lung, and
Blood Institute Registry. Chest. 2003;123:765–71.
Eden E, Strange C, Holladay B, Xie L. Asthma and
allergy in alpha-1 antitrypsin deficiency. Respir Med.
;100:1384–91.
Cuvelier A, Muir JF, Hellot MF, Benhamou D, Martin JP,
Bénichou J, et al. Distribution of alpha(1)-antitrypsin alleles
in patients with bronchiectasis. Chest. 2000;117:415–9.
Amaro R, Huerta A, Miravitlles M. Is it asthma, is it
bronchiectasis… or is it an alpha-1-antitrypsin deficiency?
Arch Bronconeumol. 2011;47:376.
Miravitlles M, Vilà S, Torrella M, Balcells E, Rodríguez-
Frías F, De la Roza C, et al. Influence of deficient alpha1-
anti-trypsin phenotypes on clinical characteristics and
severity of asthma in adults. Respir Med. 2002;96:186–92.
Demeo DL, Sandhaus RA, Barker AF, Brantly ML,
Eden E, McElvaney NG, et al. Determinants of airflow
obstruction in severe alpha-1-antitrypsin deficiency.
Thorax. 2007;62:806–13.
Malerba M, Radaeli A, Ceriani L, Tantucci C, Grassi V.
Airway hyperresponsiveness in a large group of subjects
with alpha1-antitrypsin deficiency: a cross-sectional
controlled study. J Intern Med. 2003;253:351–8.
Vignola AM, Bonanno A, Mirabella A, Riccobono L,
Mirabella F, Profita M, et al. Increased levels of elastase and
alpha1-antitrypsin in sputum of asthmatic patients. Am J
Respir Crit Care Med. 1998;157:505–11.
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald
JM, Chetta A, et al.; MENSA Investigators. Mepolizumab
treatment in patients with severe eosinophilic asthma. N
Engl J Med. 2014;371:1198–207.
Murphy K, Jacobs J, Bjermer L, Fahrenholz JM, Shalit
Y, Garin M, et al. Long-term Safety and Efficacy of
Reslizumab in Patients with Eosinophilic Asthma. J Allergy
Clin Immunol Pract. 2017;5:1572–81.
FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG,
Hirsch I, Metcalfe P, et al. Predictors of enhanced response
with benralizumab for patients with severe asthma: pooled
analysis of the SIROCCO and CALIMA studies. Lancet
Respir Med. 2018;6:51–64.
Blanco I, Canto H, Flores J, Camblor C, Cárcaba V, De
Serres FJ, et al. Long-term augmentation therapy with
alpha-1 antitrypsin in an MZ-AAT severe persistent
asthma. Monaldi Arch Chest Dis. 2008;69:178–82.
Enlaces refback
- No hay ningún enlace refback.